What's New

Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication and Dosage & Administration of Breast Cancer with HER2 Overexpression

2018/11/28

Tokyo, Japan, November 28, 2018 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) today announced that it obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) , for additional indication and dosage and administration of breast cancer with HER2 overexpression for Trastuzumab BS for I.V. Infusion 60mg “NK” ・150mg “NK”(hereinafter referred to as “Trastuzumab BS “NK”).
Trastuzumab BS “NK” is a biosimilar of the trastuzumab, humanized anti-human HER2 monoclonal antibody. In this March, Nippon Kayaku obtained the manufacture and marketing approval with the indication of unresectable advanced or recurrent gastric cancer with HER2 overexpression and has been marketing since this August.
With expanding the indication of Trastuzumab BS “NK”, Nippon Kayaku expects to make a significant contribution to the patients, their families and medical professionals.


【Reference】
The underlined descriptions are newly added or changed.
Product nameTrastuzumab BS for I.V. Infusion 60mg “NK”
Trastuzumab BS for I.V. Infusion 150mg “NK”
Generic nameTrastuzumab(Genetical Recombination)[Trastuzumab Biosimilar 1]
Indications

Breast cancer with HER2 overexpression

Advanced or recurrent gastric cancer with HER2 overexpression, not amenable to curative resection
Dosage and administration

Regimen A should be used for breast cancer with HER2 overexpression.

Regimen B should be used concomitantly with other anticancer drugs for advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection.

Regimen A:
Usually for adults, an initial dose of 4 mg trastuzumab per kilogram body weight, and subsequent doses of 2 mg/kg, are administered as a single intravenous infusion over at least 90 minutes once a week.

Regimen B:
Usually for adults, an initial dose of 8 mg trastuzumab per kilogram body weight, and subsequent doses of 6 mg/kg, are administered as a single intravenous infusion over at least 90 minutes once every three weeks.
If the first infusion is well tolerated, the subsequent infusions may be shortened to 30 minutes.



[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR